Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib

被引：53

作者：

Hayashi, Yoshiki ^{[1
]}

Nakamae, Hirohisa ^{[1
]}

Katayama, Takako ^{[1
]}

Nakane, Takahiko ^{[1
]}

Koh, Hideo ^{[1
]}

Nakamae, Mika ^{[1
]}

Hirose, Asao ^{[1
]}

Hagihara, Kiyoyuki ^{[1
]}

Terada, Yoshiki ^{[1
]}

Nakao, Yoshitaka ^{[1
]}

Hino, Masayuki ^{[1
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 06期

关键词：

Imatinib; nilotinib; dasatinib; NK-cell reactivity; cytokine; chemokine; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; NATURAL-KILLER; NK-CELLS; PROLIFERATION; EXPANSION; THERAPY; TARGETS;

D O I：

10.3109/10428194.2011.647017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunomodulation induced by dasatinib is reportedly related to better prognosis in chronic myeloid leukemia (CML). However, the underlying mechanism has not yet been fully elucidated. The immunoprofiles of 63 patients in the chronic phase of CML were evaluated during treatment with a tyrosine kinase inhibitor (imatinib, n = 36; nilotinib, n = 9; dasatinib, n = 18). The numbers of CD56 + CD57 + and CD3 + CD57 + cells increased significantly in the dasatinib group. The numbers of regulatory T-cells were comparable among the three groups. Dasatinib markedly enhanced natural killer (NK)-cell reactivity. Only one patient treated with dasatinib showed a slight cytomegalovirus (CMV) reactivation. In contrast, nilotinib suppressed NK-cell reactivity. Plasma levels of interleukin-8 (IL-8), interferon-gamma inducible protein-10 (IP-10) and monocyte chemoattractant protein-1 (MCP-1) were significantly elevated in all three groups, and plasma levels of granulocyte macrophage-colony stimulating factor (GM-CSF) were significantly elevated in the imatinib and dasatinib groups. Our results suggest the presence of a mechanism for dasatinib-associated immunomodulatory effects that is distinct from CMV reactivation and a decreased number of regulatory T-cells.

引用

页码：1084 / 1089

页数：6

共 16 条

[1] Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors [J].

Bantscheff, Marcus ;

Eberhard, Dirk ;

Abraham, Yann ;

Bastuck, Sonja ;

Boesche, Markus ;

Hobson, Scott ;

Mathieson, Toby ;

Perrin, Jessica ;

Raida, Manfred ;

Rau, Christina ;

Reader, Valerie ;

Sweetman, Gavain ;

Bauer, Andreas ;

Bouwmeester, Tewis ;

Hopf, Carsten ;

Kruse, Ulrich ;

Neubauer, Gitte ;

Ramsden, Nigel ;

Rick, Jens ;

Kuster, Bernhard ;

Drewes, Gerard .

NATURE BIOTECHNOLOGY, 2007, 25 (09) :1035-1044

[2] Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture [J].

Cervantes, F ;

Pierson, BA ;

McGlave, PB ;

Verfaillie, CM ;

Miller, JS .

BLOOD, 1996, 87 (06) :2476-2485

[3] Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling [J].

Chen, J. ;

Schmitt, A. ;

Chen, B. ;

Rojewski, M. ;

Ruesseler, V. ;

Fei, F. ;

Yu, Y. ;

Yu, X. ;

Ringhoffer, M. ;

von Harsdorf, S. ;

Greiner, J. ;

Goetzz, M. ;

Guillaume, P. ;

Doehner, H. ;

Bunjes, D. ;

Schmitt, M. .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2008, 12 (5B) :2107-2118

[4] Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells [J].

de Jager, W ;

te Velthuis, H ;

Prakken, BJ ;

Kuis, W ;

Rijkers, GT .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (01) :133-139

[5] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) [J].

Hughes, Timothy P. ;

Hochhaus, Andreas ;

Branford, Susan ;

Mueller, Martin C. ;

Kaeda, Jaspal S. ;

Foroni, Letizia ;

Druker, Brian J. ;

Guilhot, Francois ;

Larson, Richard A. ;

O'Brien, Stephen G. ;

Rudoltz, Marc S. ;

Mone, Manisha ;

Wehrle, Elisabeth ;

Modur, Vijay ;

Goldman, John M. ;

Radich, Jerald P. .

BLOOD, 2010, 116 (19) :3758-3765

[6] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].

Kantarjian, Hagop ;

Shah, Neil P. ;

Hochhaus, Andreas ;

Cortes, Jorge ;

Shah, Sandip ;

Ayala, Manuel ;

Moiraghi, Beatriz ;

Shen, Zhixiang ;

Mayer, Jiri ;

Pasquini, Ricardo ;

Nakamae, Hirohisa ;

Huguet, Francoise ;

Boque, Concepcion ;

Chuah, Charles ;

Bleickardt, Eric ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Szatrowski, Ted ;

Shapiro, David ;

Baccarani, Michele .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270

[7] Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia [J].

Kim, Dong Hwan ;

Kamel-Reid, Suzanne ;

Chang, Hong ;

Sutherland, Robert ;

Jung, Chul Won ;

Kim, Hyeoung-Joon ;

Lee, Je-Jung ;

Lipton, Jeffrey H. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01) :135-139

[8] Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation [J].

Kreutzman, A. ;

Ladell, K. ;

Koechel, C. ;

Gostick, E. ;

Ekblom, M. ;

Stenke, L. ;

Melo, T. ;

Einsele, H. ;

Porkka, K. ;

Price, D. A. ;

Mustjoki, S. ;

Seggewiss, R. .

LEUKEMIA, 2011, 25 (10) :1587-1597

[9] Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy [J].

Mustjoki, S. ;

Ekblom, M. ;

Arstila, T. P. ;

Dybedal, I. ;

Epling-Burnette, P. K. ;

Guilhot, F. ;

Hjorth-Hansen, H. ;

Hoglund, M. ;

Kovanen, P. ;

Laurinolli, T. ;

Liesveld, J. ;

Paquette, R. ;

Pinilla-Ibarz, J. ;

Rauhala, A. ;

Shah, N. ;

Simonsson, B. ;

Sinisalo, M. ;

Steegmann, J. L. ;

Stenke, L. ;

Porkka, K. .

LEUKEMIA, 2009, 23 (08) :1398-1405

[10] Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion [J].

Nagata, Yasunobu ;

Ohashi, Kazuteru ;

Fukuda, Shiomi ;

Kamata, Noriko ;

Akiyama, Hideki ;

Sakamaki, Hisashi .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (05) :799-807

← 1 2 →